REFERENCES


• Agarwal A., Kukreti G., Juyal N., Yadav ., (2012), Niosomes as targeted drug systems of delivery , IJ PSRR ,12(1), 53-60


• Banker G. S., Rodes C. T., (1979), Modern Pharmacist Marcel Dekker, New York, 240(2), 263-311.
• Beissert S., Schwarz T., (2002), Role of immunomodulation in diseases responsive to phototherapy Methods, 28, 138–144.


• Boguniewicz M., Hultsch T., Eichenfield L.F., Colo D., Diego S., Calif, Mainz, (2003), Current management of atopic dermatitis and interruption of the atopic march, J. allergy clin immu., 112(6),140-150.


• Cavey D., Caron J. C., Shroot B., (1981), Anthralin chemical instability and glucose-6-phosphate dehydrogenase inhibition, J Pharm Sci, 71(9), 980-983.


• Dibbern H.W., Wirbitzki E., Muller R.M., (2002), UV and IR spectra: Pharmaceutical substances (UV and IR and pharmaceutical and cosmetic excipients (IR), Aulendorf: Editio Cantor Verlag, 493-444.
• Ellis, C.N., (2007), Placebo response in two long-term randomized psoriasis studies that were negative for rosiglitazone. Am. J. Clin. Der.8, 93–102.
• Halsall, J.A., (2005), Skin, the final frontier, Int J Pharm., 224(1), 1-18.


• Indian Pharmacopoeia (2010), Government of India, Ministry of Health and Family welfare, Published by The Indian Pharmacopoeia Commission Ghaziabad, (2), 1240-1241.


• Katz H.I., Tanner D.J., Cuffie C.A., (1998), A comparison of the efficacy and safety of the combination Mometasone furoate 0.1 % salicylic acid 5 % ointment with each of its component in psoriasis, J Dermatol Treat, 9, 151-156.
• Koo J., Tanner D.J., Cuffie C.A., (1998), Mometasone furoate 0.1 % salicylic acid 5 % ointment versus mometasone furoate 0.1 % in the treatment of moderate-to-severe psoriasis: a multicenter study, Clin Ther, 20, 283-291.


• Lawrence M.J., Lawrence S.M., Chauhan S., Barlow D.J., (1996), The formation, characterization and stability of non-ionic surfactant vesicles, STP Pharm Sci, 1, 49-60.


• Mahrous G. M., (2010), Proniosomes as a drug carrier for transdermal delivery of meloxicam, BPSci., 33 (2), 131-140.
• Mishra S., Vasistha P., Sachdeva M.S.,(2013), Formulation, optimization and characterization of proniosomal gel for transdermal delivery of naproxen, WJPPS, 2(2), 554-569.


• Mustakallio K. K., (1979), Irritation and staining by dithranol (anthralin) and related compounds: Estimation with chamber testing and contact thermography, Acta Derm Venereol Suppl (Stockh), 59, 125–132.


• OECD Guideline for Testing Of Chemicals” 402, Adopted 24 Feb 1987
• Parikh D.K., Ghosh T.K., (2005), Feasibility of transdermal delivery of fluoxetine, AAPS PharmSciTech, 6(2), 144–149.
• Pittlekow M and Genebriera J. Psoriasis, Pharmacology and therapeutic principles to practice expert consult premium edition, pp 983-105
• Raab W. P., Gmeiner B. M., (1975), Influence of ultraviolet light, various temperatures, and zinc ions on anthralin (dithranol), Dermatologica, 150, 267-276.


• Reddy D.N., Udupa N.,(1993), Formulation and evaluation of oral and transdermal preparations of flurbiprofen and piroxicam incorporated with different carriers, Drug Dev Ind Pharm, 19, 843–852.

• Reich K., Mrowietz U., (2007), Treatment goals in psoriasis, JDDG, 7(5), 566-574.


• Ternowitz T. (1987), The enhanced monocyte and neutrophil chemotaxis in psoriasis is normalized after treatment with psoralens plus ultraviolet A and anthralin. J Am Acad Dermatol, 16(6), 1169-75.


• Thomas L. and Viswanad V., (2012), Formulation and Optimization of Clotrimazole-Loaded Proniosomal Gel Using 3² Factorial Design, Sci Pharm, 80, 731–748


• Tripathi G. and Dubey B.K. (2011) In-vitroocclusion studies of solid lipid nanoparticles loaded hydrogel by water vapour permeability analysis, Journal of Global Pharma Technology, 3(4), 14-20


